Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028974 · ClinicalTrials.gov registry record · Phase 4
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 77
- Enrollment target
NCT03028974: Completed Phase 4 study, sponsored by Stanford University.
NCT03028974 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03028974, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 77 participants
- Enrollment target
Study Summary
The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.
Interventions
- BIOLOGICAL Fluzone®
- BIOLOGICAL FluMist®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2014-09-17 |
| Est. Completion | 2017-11-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03028974
The ClinicalTrials.gov registry entry for NCT03028974 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone® is the first listed.
NCT03028974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03028974 about?
NCT03028974 is a clinical study titled "Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)". The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.
What is the current status of trial NCT03028974?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2014-09-17. Estimated completion is 2017-11-20.
What interventions are being tested in trial NCT03028974?
The interventions under investigation include: Fluzone® (BIOLOGICAL), FluMist® (BIOLOGICAL).
Who is sponsoring clinical trial NCT03028974?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.